The forecasts for 2023 indicate Croatia leading in per capita sales at $37.7, followed by Iceland at $21.1 and Germany at $18.8. Notable year-on-year variations show significant increases in South Korea (8.27%) and Australia (3.05%), whereas Greece, Norway, and Luxembourg experienced declines of -3.06%, -3.06%, and -3.23%, respectively. The 5-year Compound Annual Growth Rate (CAGR) analysis reveals stable or moderate growth across most countries, with few experiencing marginal decreases. Germany shows a strong positive trend with a 2.28% increase, reflecting consistent demand.
Future Trends
Looking ahead, increasing demand for personalized medicine, advancements in biotechnology, and greater awareness of hormonal disorders are expected to drive market growth globally. However, economic conditions and healthcare policies will play crucial roles in shaping per capita sales across different regions.
Top countries in Systemic Hormonal Preparations Sales (Excluding Sex Hormones and Insulins) by Country
| # | 10 Countries | US Dollars Per Capita | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Croatia | 37.7 | 2023 | +2.72% | +1.73% | View data |
| 2 | 2 Iceland | 21.1 | 2023 | +1.93% | +1.18% | View data |
| 3 | 3 Germany | 18.8 | 2023 | +2.17% | +2.28% | View data |
| 4 | 4 Greece | 12.5 | 2023 | +0.81% | -3.06% | View data |
| 5 | 5 Belgium | 12.1 | 2023 | +0.83% | -1.42% | View data |
| 6 | 6 Norway | 11.3 | 2023 | +0.89% | -3.06% | View data |
| 7 | 7 Luxembourg | 10.1 | 2023 | +1% | -3.23% | View data |
| 8 | 8 Spain | 9.8 | 2023 | +3.16% | -0.2% | View data |
| 9 | 9 Czech Republic | 9.3 | 2023 | +3.33% | +1.34% | View data |
| 10 | 10 Australia | 8.6 | 2023 | +3.61% | +3.05% | View data |
